The human G1m1 allotype associates with CD4 T-cell responsiveness to a highly conserved IgG1 constant region peptide and confers an asparaginyl endopeptidase cleavage site

Genes and Immunity

Volumn 12, Issue 3, 2011, Pages 213-221

  Stickler, M M ^a   Reddy, A ^a   Xiong, J M ^a   Hinton, P R ^a   Dubridge, R ^a   Harding, F A ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

allotype; CD4+ T cells; human; immunogenicity; immunoglobulin; proteolysis

Indexed keywords

CYTOKINE; HLA DR ANTIGEN; IMMUNOGLOBULIN G1; LEGUMAIN; PROTEIN G 1 M 1; UNCLASSIFIED DRUG;

ALLOTYPE; AMINO ACID SEQUENCE; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; HOMOZYGOSITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN DEGRADATION;

AMINO ACID SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CONSERVED SEQUENCE; CYSTEINE ENDOPEPTIDASES; CYTOKINES; EPITOPES; HETEROZYGOTE; HLA-DR ANTIGENS; HOMOZYGOTE; HUMANS; IMMUNOGLOBULIN CONSTANT REGIONS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN GM ALLOTYPES; MOLECULAR SEQUENCE DATA; PEPTIDES;

EID: 79955468826     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2010.68     Document Type: Article

References (49)

1. Lefranc M-P, Lefranc G. The Immunoglobulin FactsBook. Academic Press: San Diego, 2001.
2. Schroeder Jr HW, Hillson JL, Perlmutter RM. Early restriction of the human antibody repertoire. Science 1987; 238: 791-793. (Pubitemid 18005236)
3. Faure M, Sanchez P, Cazenave PA, Rueff-Juy D. Tcell tolerance to kappa light chain (L kappa): identification of a naturally processed self-C kappa-peptidic region by specific CD4+ Tcell hybridomas obtained in L kappa-deficient mice. Cell Immunol 1997; 180: 84-92. (Pubitemid 27433621)
4. Lieberman R, Humphrey Jr W. Association of H-2 types with genetic control of immune reponsiveness to IgG (gamma2a) allotypes in the mouse. J Exp Med 1972; 136: 1222-1230.
5. Bruggemann M, Winter G, Waldmann H, Neuberger MS. The immunogenicity of chimeric antibodies. J Exp Med 1989; 170: 2153-2157. (Pubitemid 20010093)
6. de Lange GG. Polymorphisms of human immunoglobulins: Gm, Am, Em and Km allotypes. Exp Clin Immunogenet 1989; 6: 7-17. (Pubitemid 18267864)
7. Lefranc G, Lefranc M-P. Gm allotype and GM haplotypes. IMGT Repertoire (IG and TCR) IMGT: The International Immuno genetics Information System 2010.
8. Lefranc G, Marie-Paule L. Prevalent Gm haplotypes of the human IGHG3, IGHG1 and IGHG2 alleles in different populations. IMGT Repertoire (IG and TCR) IMGT: The International Immuno genetics Information System 2010.
9. Jefferis R, Lefranc MP. Human immunoglobulin allotypes: possible implications for immunogenicity. MAbs 2009; 1: 332-338.
10. Lefranc MP, Pommie C, Kaas Q, Duprat E, Bosc N, Guiraudou D et al. IMGT unique numbering for immunoglobulin and T cell receptor constant domains and Ig superfamily C-like domains. Dev Comp Immunol 2005; 29: 185-203. (Pubitemid 39575119)
11. Johnson MJ, de Lange G, Cavalli-Sforza LL. Ig gamma restriction fragment length polymorphisms indicate an ancient separation of Caucasian haplotypes. Am J Hum Genet 1986; 38: 617-640. (Pubitemid 16057809)
12. Atherton A, Armour KL, Bell S, Minson AC, Clark MR. The herpes simplex virus type 1 Fc receptor discriminates between IgG1 allotypes. Eur J Immunol 2000; 30: 2540-2547.
13. Pandey JP, Namboodiri AM, Luo Y, Wu Y, Elston RC, Thomas DL et al. Genetic markers of IgG influence the outcome of infection with hepatitis C virus. J Infect Dis 2008; 198: 1334-1336.
14. Grubb R. Agglutination of erythrocytes coated with incomplete anti-Rh by certain rheumatoid arthritic sera and some other sera; the existence of human serum groups. Acta Pathol Microbiol Scand 1956; 39: 195-197.
15. Grubb R, Abrahamson M, Grubb A. Assignment of allotypes G1m(a+) and G1m(a) at the genomic level by polymerase chain reaction analysis. Exp Clin Immunogenet 1990; 7: 205-212.
16. Kickler TS, Ness PM, Braine HG, Richardson L, Farkosh M. The expression of IgG allotypes on platelets and immunization to IgG allotypes in multitransfused thrombocytopenic patients. Blood 1990; 76: 849-852. (Pubitemid 20253304)
17. Fudenberg HH, Fudenberg BR. Antibody to hereditary human gamma-globulin (Gm) factor resulting from maternal-fetal incompatibility. Science 1964; 145: 170-171.
18. Allen JC, Kunkel HG. Antibodies to genetic types of gamma globulin after multiple transfusions. Science 1963; 139: 418-419.
19. Bikoff E, Birshtein BK. T cell clones specific for IgG2a of the a allotype: direct evidence for presentation of endogenous antigen. J Immunol 1986; 137: 28-34. (Pubitemid 16100263)
20. Eyerman MC, Wysocki L. T cell recognition of somaticallygenerated Ab diversity. J Immunol 1994; 152: 1569-1577.
21. Eyerman MC, Zhang X, Wysocki LJ. T cell recognition and tolerance of antibody diversity. J Immunol 1996; 157: 1037-1046.
22. Guo W, Smith D, Guth A, Aviszus K, Wysocki LJ. T cell tolerance to germline-encoded antibody sequences in a lupusprone mouse. J Immunol 2005; 175: 2184-2190. (Pubitemid 41113824)
23. Snyder CM, Aviszus K, Heiser RA, Tonkin DR, Guth AM, Wysocki LJ. Activation and tolerance in CD4(+) T cells reactive to an immunoglobulin variable region. J Exp Med 2004; 200: 1-11. (Pubitemid 38924723)
24. Saeki Y, Chen JJ, Shi LF, Kohler H. Idiotypic intramolecular help. Induction of tumor-specific antibodies by monoclonal anti-idiotypic antibody with the help of Fc-specific T helper clones. J Immunol 1989; 142: 2629-2634. (Pubitemid 19114874)
25. Mazel SM, Rudensky AY, Yurin VL. Immunoglobulin-specific T-B cell interaction. III. B cell activation by immunoglobulinrecognizing T cell clones. Eur J Immunol 1990; 20: 833-839. (Pubitemid 20167039)
26. Rudensky AY, Yurin VL. Immunoglobulin-specific T-B cell interaction. I. Presentation of self immunoglobulin determinants by B lymphocytes. Eur J Immunol 1989; 19: 1677-1683. (Pubitemid 19243888)
27. Yurin VL, Rudensky AY, Mazel SM, Blechman JM. Immunoglobulin- specific T-B cell interaction. II. T cell clones recognize the processed form of B cell's own surface immunoglobulin in the context of the major histocompatibility complex class II molecule. Eur J Immunol 1989; 19: 1685-1691. (Pubitemid 19243889)
28. Watts C, Matthews SP, Mazzeo D, Manoury B, Moss CX. Asparaginyl endopeptidase: case history of a class II MHC compartment protease. Immunol Rev 2005; 207: 218-228. (Pubitemid 41415020)
29. Li DN, Matthews SP, Antoniou AN, Mazzeo D, Watts C. Multistep autoactivation of asparaginyl endopeptidase in vitro and in vivo. J Biol Chem 2003; 278: 38980-38990. (Pubitemid 37221799)
30. Halfon S, Patel S, Vega F, Zurawski S, Zurawski G. Autocatalytic activation of human legumain at aspartic acid residues. FEBS Lett 1998; 438: 114-118. (Pubitemid 28517846)
31. Savelyeva N, King CA, Vitetta ES, Stevenson FK. Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help. Proc Natl Acad Sci USA 2005; 102: 10987-10992. (Pubitemid 41105980)
32. Watts C, Moss CX, Mazzeo D, West MA, Matthews SP, Li DN et al. Creation versus destruction of T cell epitopes in the class II MHC pathway. Ann N Y Acad Sci 2003; 987: 9-14. (Pubitemid 36584002)
33. Newcomb JR, Cresswell P. Characterization of endogenous peptides bound to purified HLA-DR molecules and their absence from invariant chain-associated alpha beta dimers. J Immunol 1993; 150: 499-507. (Pubitemid 23133625)
34. Flobakk M, Rasmussen IB, Lunde E, Frigstad T, Berntzen G, Michaelsen TE et al. Processing of an antigenic sequence from IgG constant domains for presentation by MHC class II. J Immunol 2008; 181: 7062-7072.
35. Lunde E, Munthe LA, Vabo A, Sandlie I, Bogen B. Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells. Nat Biotechnol 1999; 17: 670-675. (Pubitemid 29316145)
36. Lunde E, Bogen B, Sandlie I. Immunoglobulin as a vehicle for foreign antigenic peptides immunogenic to T cells. Mol Immunol 1997; 34: 1167-1176.
37. Magdelaine-Beuzelin C, Vermeire S, Goodall M, Baert F, Noman M, Assche GV et al. IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. Pharmacogenet Genomics 2009; 19: 383-387.
38. Isaacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, Cobbold SP et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992; 340: 748-752.
39. Giudicelli V, Chaume D, Lefranc MP. IMGT/GENE-DB: a comprehensive database for human and mouse immunoglobulin and T cell receptor genes. Nucleic Acids Res 2005; 33 (Database issue): D256-D261. (Pubitemid 40207873)
40. Ellison JW, Berson BJ, Hood LE. The nucleotide sequence of a human immunoglobulin C gamma1 gene. Nucleic Acids Res 1982; 10: 4071-4079.
41. Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005; 23: 1105-1116. (Pubitemid 41486392)
42. Ritter G, Cohen LS, Williams Jr C, Richards EC, Old LJ, Welt S. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res 2001; 61: 6851-6859. (Pubitemid 32896510)
43. Bender NK, Heilig CE, Droll B, Wohlgemuth J, Armbruster FP, Heilig B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007; 27: 269-274. (Pubitemid 46088257)
44. West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008; 28: 1122-1126.
45. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 4285-4289.
46. Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods 2005; 36: 3-10. (Pubitemid 40558811)
47. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1739-1745.
48. Stickler M, Chin R, Faravashi N, Gebel W, Razo OJ, Rochanayon N et al. Human population-based identification of CD4(+) T-cell peptide epitope determinants. J Immunol Methods 2003; 281: 95-108. (Pubitemid 37324573)
49. Stickler MM, Estell DA, Harding FA. CD4+ T-cell epitope determination using unexposed human donor peripheral blood mononuclear cells. J Immunother 2000; 23: 654-660.